Sanders Morris Harris LLC Has $848,000 Position in AstraZeneca PLC (NASDAQ:AZN)

Sanders Morris Harris LLC raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,929 shares of the company’s stock after buying an additional 557 shares during the period. Sanders Morris Harris LLC’s holdings in AstraZeneca were worth $848,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of AZN. Stratos Wealth Advisors LLC grew its holdings in AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after acquiring an additional 133 shares during the last quarter. Crumly & Associates Inc. lifted its holdings in AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after buying an additional 143 shares in the last quarter. Harbour Investments Inc. boosted its position in AstraZeneca by 1.9% in the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after buying an additional 160 shares during the last quarter. Smith Salley Wealth Management increased its stake in shares of AstraZeneca by 1.0% in the 3rd quarter. Smith Salley Wealth Management now owns 16,158 shares of the company’s stock valued at $1,259,000 after buying an additional 162 shares during the period. Finally, Veracity Capital LLC increased its position in AstraZeneca by 4.5% in the third quarter. Veracity Capital LLC now owns 3,833 shares of the company’s stock worth $299,000 after purchasing an additional 164 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Up 0.3 %

Shares of NASDAQ AZN opened at $65.90 on Thursday. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a market cap of $204.33 billion, a price-to-earnings ratio of 31.53, a P/E/G ratio of 1.05 and a beta of 0.46. The company’s fifty day moving average is $65.98 and its 200-day moving average is $74.69.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.87 earnings per share. Equities research analysts predict that AstraZeneca PLC will post 4.11 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.